Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 6/20 | 0.44 |
| ▸ | LCK | P06239 | 5/20 | 0.44 |
| ▸ | BTK | Q06187 | 4/20 | 0.44 |
| ▸ | CAMK1D | Q8IU85 | 7/20 | 0.41 |
| ▸ | F10 | P00742 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30160804 | 0.91 | JAK3 (0.40) | JAK3LCKBTKCAMK1DF10 | |
| SCHEMBL30165823 | 0.89 | JAK3 (0.46) | JAK3LCKBTKCAMK1DF10 | |
| SCHEMBL30165869 | 0.88 | SCN9A (0.47) | JAK3LCKBTK | |
| SCHEMBL30160681 | 0.83 | JAK3 (0.52) | JAK3LCKBTKEGFR | |
| SCHEMBL30160759 | 0.83 | JAK3 (0.52) | JAK3LCKBTKEGFR | |
| SCHEMBL30165816 | 0.82 | JAK3 (0.42) | JAK3LCKBTKEGFR | |
| SCHEMBL30165878 | 0.81 | BTK (0.41) | JAK3LCKBTKCAMK1DEGFR | |
| SCHEMBL30165854 | 0.81 | CAMK1D (0.39) | JAK3LCKBTKCAMK1D | |
| SCHEMBL30165804 | 0.80 | JAK3 (0.49) | JAK3LCKBTKEGFR | |
| SCHEMBL30165833 | 0.80 | BTK (0.38) | JAK3LCKBTKCAMK1DEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360146-A1 | BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2024-10-31 | — | — | US | disclosed |
| CN-115557933-B | Bruton tyrosine kinase and mutant degradation agent, composition and application thereof | 杭州和正医药有限公司 | 2024-08-16 | — | — | CN | disclosed |
| EP-4342892-A1 | BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF | Hangzhou Healzen Therapeutics Co., Ltd. (CN) | 2024-03-27 | — | — | EP | disclosed |
| WO-2023274390-A1 | BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF | 杭州和正医药有限公司 | 2023-01-05 | — | — | WO | disclosed |
| CN-115557933-A | Bruton tyrosine kinase and mutant degradation agent, composition and application thereof | 杭州和正医药有限公司 | 2023-01-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360146-A1 | BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF | BTK, ZAP70, SYK | JAK3 197/4885LCK 23/4885BTK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.